Navigation Links
Kendle Announces Details Regarding Second Quarter 2010 Earnings Conference Call and Webcast
Date:7/14/2010

CINCINNATI, July 14 /PRNewswire/ -- Kendle (Nasdaq: KNDL) announced today it will release its second quarter 2010 financial results after the market closes on Wednesday, Aug. 4, 2010. The Company will host a telephone conference call and simultaneous webcast on Thursday, Aug. 5 at 8:30 a.m. Eastern Time. A question and answer session will follow.

Conference Call Instructions

To participate in the telephone conference call, interested parties in the United States and Canada should dial (800) 946-0709. Participants outside North America should dial (719) 457-2632. All participants should enter conference ID number 5419062. A replay will be available through 5 p.m. Eastern Time on Sept. 7, 2010, by dialing (888) 203-1112 in North America or 719-457-0820 outside of North America and entering conference ID number 5419062.

Webcast Instructions

To access the live webcast, visit

http://ir.kendle.com/phoenix.zhtml?p=irol-eventDetails&c=88712&eventID=3210368

Instructions for accessing the webcast are provided at the site. The webcast will be archived at www.kendle.com (click on "For Investors" and then "Events & Presentations") shortly after the call for on-demand replay through 5 p.m. Eastern Time on Sept. 7, 2010.  Please note that webcast participants will not be able to ask questions.

System requirements for the webcast include Windows Media Player software and at least a 28.8 Kbps connection to the Internet. Media Player is downloadable at no charge from http://www.microsoft.com/windows/windowsmedia/default.aspx.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kendle Experts to Present at the Drug Information Association 44th Annual Meeting
2. Kendle Experts to Share Insights at the Regulatory Affairs Professionals Society Annual Conference and Exhibition
3. Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast
4. Kendle Appoints J. Michael Sprafka, MPH, PhD, Vice President, Kendle Consulting
5. Kendle Receives Approval From Indian Government to Proceed With Development of Operations Center in Special Economic Zone
6. Kendle Launches New Global Biostatistics Infrastructure
7. Kendle is First Global CRO to Achieve ISO 9001:2008 Certification in China Through Beijing Affiliate
8. Kendle Executive to Share Insights at World Pharma Trials Asia 2010
9. Kendle Director of Global Safety and Pharmacovigilance, Drew Kilpatrick, PhD, Named One of Ten Notable People in R&D
10. Kendle Advances Early Stage Drug Development with ElMindAs Innovative Brain Network Activation Technology
11. Kendle to Present at 2010 Wells Fargo Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... YORK , December 8, 2016 ... focused on the research, distribution, and marketing of pharmaceutical ... affected by patent protection and expiration. Additionally, these firms ... Healthcare sector as a whole. Up for review this ... ), Synergy Pharmaceuticals Inc. (NASDAQ: SGYP ), ...
(Date:12/8/2016)... DES MOINES, Iowa , Dec. 8, 2016 ... STLT), a pharmaceutical company advancing technologies designed to ... the appointment of Chitra Edwin , Ph.D., ... and Compliance. Dr. Edwin will provide leadership for ... planning for regulatory approvals, preparation of regulatory submissions, ...
(Date:12/7/2016)... , Dec. 7, 2016 "Lantus (Insulin Glargine) Biosimilar Clinical Trial ... 37 biosimilar version of Lantus drug in clinical pipeline. Currently 5 biosimilar ... Japan , Kenya , ... , China , Slovakia , ... & 2 diabetes mellitus. The patent on Lantus expired in 2014. ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp ... in and around the greater Phoenix metropolitan region, is announcing a charity event ... mission of the Homeless Youth Connection is to promote community awareness of the ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, ... residential and commercial clients in the northern Alabama and Georgia regions, is embarking ... Since 1977, Nobis Works has built a network of support and education facilities ...
(Date:12/7/2016)... ... December 07, 2016 , ... Students attending Envision’s ... unique opportunity to get hands-on experience in an emergency medical simulation, When Care ... to gain invaluable, real-life medical skills that are critical success in a future ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... the drug in their bodies, a researcher at the Icahn School of Medicine ... Research. , The study found that when young children are exposed to secondhand ...
(Date:12/7/2016)... PHILADELPHIA, PA (PRWEB) , ... December 07, 2016 ... ... story of a women growing up with a schizophrenic mother in a unique, ... social worker who specializes in treating trauma and addictive disorders at her private ...
Breaking Medicine News(10 mins):